HER2-Positive Early Breast Cancer: Reviewing DESTINY-Breast05 and Residual Disease Management

Dr. Neil Iyengar shifts the discussion to the management of residual disease in HER2-positive early breast cancer, inviting Dr. Alison Conlin to review the phase III DESTINY-Breast05 trial. The faculty discuss the high-risk patient population enrolled in the study, including those with residual invasive disease following neoadjuvant therapy, and compare the investigational strategy with the previously established adjuvant standard of care. Dr. Conlin highlights the observed improvement in invasive disease-free survival, while emphasizing the importance of careful toxicity monitoring when incorporating newer therapies into the curative setting. The panel also considers the clinical implications of introducing more effective therapies earlier in the treatment course and discusses how the DESTINY-Breast05 findings may influence adjuvant treatment selection for patients with persistent residual disease after neoadjuvant therapy, while balancing efficacy with long-term safety considerations.